Clinical trial

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

NCT03112590

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-06-23

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2017-06-23Date precision: day

Registry last updated2023-04-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Breast Cancer, Maleunresolved

Breast Cancer Femaleunresolved

HER2-positive Breast Cancerunresolved

Interventions

Interferon-gamma (IFN-γ)BIOLOGICAL

PaclitaxelDRUG · verified · RxNorm: paclitaxel

TrastuzumabDRUG · verified · RxNorm: trastuzumab

PertuzumabOTHER

Post Therapy SurgeryPROCEDURE

Sponsors & collaborators

H. Lee Moffitt Cancer Center and Research Institutelead sponsor

Horizon Pharma Ireland, Ltd., Dublin Irelandcollaborator

Mapped research locations

TampaFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03112590 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.